Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products

Rapid Communications in Mass Spectrometry

Volumn 26, Issue 6, 2012, Pages 686-692

  Esposito, Simone ^a   Deventer, Koen ^a   Eenoo, Peter Van ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

BLACK MARKET; GROWTH FACTOR; INSULIN-LIKE GROWTH FACTOR; LOWER RESOLUTION; MARKET PRODUCTS; ORBITRAP; PROPERTY; SPLICE VARIANTS; THERAPEUTIC USE; WORLD ANTI-DOPING AGENCY;

SPORTS;

EID: 84857073667     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6144     Document Type: Article

References (25)

1. World Anti-Doping Agency (WADA), The 2011 Prohibited List Iinternational Standards, 2011. Available: http://www.wada-ama.org/Documents/World-Anti-Doping- Program/WADP-Prohibited-list/To-be-effective/WADA-Prohibited-List-2011-EN.pdf.
2. M. Kohler, A. Thomas, K. Walpurgis, K. Terlouw, W. Schänzer, M. Thevis,. Detection of His-tagged Long-R-3-IGF-I in a black market product. Growth Horm. IGF Res. 2010, 386.
3. A. Thomas, M. Kohler, J. Mester, H. Geyer, W. Schänzer, M. Petrou, M. Thevis,. Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. Drug Test. Anal. 2010, 2, 144.
4. M. Kohler, A. Thomas, H. Geyer, M. Petrou, W. Schänzer, M. Thevis,. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test. Anal. 2010, 2, 533.
5. A. Thomas, S. Hoeppner, H. Geyer, W. Schänzer, M. Petrou, D. Kwiatkowska, A. Pokrywka, M. Thevis,. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 2011, 401, 507.
6. J. Henninge, M. Pepaj, I. Hullstein, P. Hemmersbach,. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test. Anal. 2010, 2, 647.
7. A. Thomas, S. Hoeppner, H. Geyer, W. Schänzer, M. Petrou, D. Kwiatkowska, A. Pokrywka, M. Thevis,. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 2011, 401, 507.
8. K. B. van 12/04/1974, betreffende sommige verrichtingen i.v.m. stoffen met hormonale, anti-hormonale, beta-adrenergische, anti-infectieuze, anti-parasitaire en anti-inflammatoire werking, laatst gewijzigd door het KB van 04/02/2002 (B.S. 28/02/2002)-.
9. G. Goldspink, S. D. R. Harridge,. Growth factors and muscle ageing. Exp. Gerontol. 2004, 39, 1433.
10. S. Y. Yang, G. E. Goldspink,. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002, 522, 156.
11. G. Goldspink,. Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping. Brit. J. Sport Med. 2005, 39, 787.
12. G. Goldspink,. Mechano growth factor, that is produced by the splicing of the IGF-1 gene increases muscle size and strength. Comp. Biochem. Phys. A 2009, 153, 74.
13. G. Goldspink, B. Wessner, H. Tschan, N. Bachl,. Growth factors, muscle function, and doping. Endocrin. Metab. Clin. 2010, 31, 169.
14. M. Hameed, R. W. Orrell, M. Cobbold, G. Goldspink, S. D. R. Harridge,. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J. Physiol.-London 2003, 547, 247.
15. J. M. Steinacker, W. Lormes, P. Karl-Georg, L. Gampert, Y. F. Liu,. Muscular mechano-growth factor (MGF) and IGF-1 expression during exhausting training. Med. Sci. Sport Exer. 2004, 36, 52.
16. V. Carpenter, K. Matthews, G. Devlin, S. Stuart, J. Jensen, J. Conaglen, F. Jeanplong, P. Goldspink, S. Y. Yang, G. Goldspink, J. Bass, C. McMahon,. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008, 17, 33.
17. J. Dluzniewska, A. Sarnowska, M. Beresewicz, I. Johnson, S. K. S. Srai, B. Ramesh, G. Goldspink, D.C. Gorecki, B. Zablocka, A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 2005, 19, 1896.
18. V. Carpenter, K. Matthews, G. Devlin, S. Stuart, J. Jensen, J. Conaglen, F. Jeanplong, P. Goldspink, S. Y. Yang, G. Goldspink, J. Bass, C. McMahon,. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008, 17, 33.
19. Available: http://prospector.ucsf.edu/prospector
20. M. Werle, A. Bernkop-Schnurch,. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006, 30, 351.
21. K. Deventer, W. Van Thuyne, P. Mikulcikova, P. Van Eenoo, F. T. Delbeke,. Detection of selected stimulants as contaminants in solid nutritional supplements by liquid chromatography-mass spectrometry. Food Chem. 2007, 103, 1508.
22. W. Van Thuyne, F. T. Delbeke,. Validation of a GC-MS screening method for anabolizing agents in solid nutritional supplements. Biomed. Chromatogr. 2004, 18, 155.
23. O. J. Pozo, K. Deventer, P. Van Eenoo, F. T. Delbeke,. Efficient approach for the comprehensive detection of unknown anabolic steroids and metabolites in human urine by liquid chromatography-electrospray-tandem mass spectrometry. Anal. Chem. 2008, 80, 1709.
24. T. W. Randolph,. Phase separation of excipients during lyophilization: Effects on protein stability. J. Pharm. Sci. 1997, 86, 1198.
25. H. Geyer, M. K. Parr, K. Koehler, U. Mareck, W. Schänzer, M. Thevis,. Nutritional supplements cross-contaminated and faked with doping substances. J. Mass Spectrom. 2008, 43, 892.